Japanese pharmaceutical company Eisai Co. and U.S. firm Biogen Inc. said Monday that a jointly developed Alzheimer's drug has been approved for continuous use for people with early stages of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback